Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-20

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01513525

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2012-01-20

Last Posted Date: 2019-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 350

Registration Number: NCT01513473

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Phase 1

Withdrawn

Conditions: Growth Disorder
Healthy

Interventions: Drug: somatropin

First Posted Date: 2012-01-19

Last Posted Date: 2013-09-16

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT01512095

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: oral anti-diabetic drug
Drug: liraglutide

First Posted Date: 2012-01-19

Last Posted Date: 2017-12-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 363

Registration Number: NCT01512108

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo
Drug: glimepiride

First Posted Date: 2012-01-19

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT01511692

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: metformin

First Posted Date: 2012-01-18

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 223

Registration Number: NCT01511198

Locations: 🇺🇸
Novo Nordisk Investigational Site, Charleston, West Virginia, United States

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Conditions: Diabetes
Diabetes Mellitus, Type 2
Weight Management
Medullary Thyroid Carcinoma

Interventions: Other: No treatment given

First Posted Date: 2012-01-18

Last Posted Date: 2023-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6750

Registration Number: NCT01511393

Locations: 🇺🇸
United BioSource, LLC, Morgantown, West Virginia, United States

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: metformin
Drug: placebo
Drug: glimepiride

First Posted Date: 2012-01-18

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 145

Registration Number: NCT01511172

Locations: 🇬🇧
Novo Nordisk Investigational Site, Yaxley. Peterborough, United Kingdom

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2012-01-18

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT01511185

Locations: 🇺🇸
Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States

Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide
Drug: insulin human
Drug: placebo

First Posted Date: 2012-01-18

Last Posted Date: 2015-03-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01511159

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy